YS Biopharma Statistics Share Statistics YS Biopharma has 188.33M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 188.33M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 17.1M Failed to Deliver (FTD) Shares 540 FTD / Avg. Volume 0.41%
Short Selling Information The latest short interest is 38.89K, so 0.02% of the outstanding
shares have been sold short.
Short Interest 38.89K Short % of Shares Out 0.02% Short % of Float 0.03% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -7.03 and the forward
PE ratio is 1.01.
YS Biopharma's PEG ratio is
-0.2.
PE Ratio -7.03 Forward PE 1.01 PS Ratio 1.49 Forward PS 0.1 PB Ratio 1.4 P/FCF Ratio -4.27 PEG Ratio -0.2
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for YS Biopharma.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.57,
with a Debt / Equity ratio of 0.68.
Current Ratio 1.57 Quick Ratio 1.29 Debt / Equity 0.68 Debt / EBITDA -6.49 Debt / FCF -2.08 Interest Coverage -4.52
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $889.01K Profits Per Employee $-188.2K Employee Count 773 Asset Turnover 0.4 Inventory Turnover 0.83
Taxes Income Tax 1.13M Effective Tax Rate -0.79%
Stock Price Statistics The stock price has increased by 42.66% in the
last 52 weeks. The beta is 0.54, so YS Biopharma's
price volatility has been higher than the market average.
Beta 0.54 52-Week Price Change 42.66% 50-Day Moving Average 0.84 200-Day Moving Average 0.67 Relative Strength Index (RSI) 41.08 Average Volume (20 Days) 130,559
Income Statement In the last 12 months, YS Biopharma had revenue of 687.2M
and earned -145.48M
in profits. Earnings per share was -1.56.
Revenue 687.2M Gross Profit 533.84M Operating Income -139.38M Net Income -145.48M EBITDA -76.82M EBIT -108.7M Earnings Per Share (EPS) -1.56
Full Income Statement Balance Sheet The company has 370.11M in cash and 498.63M in
debt, giving a net cash position of -128.52M.
Cash & Cash Equivalents 370.11M Total Debt 498.63M Net Cash -128.52M Retained Earnings -1.87B Total Assets 1.51B Working Capital -56.24M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -182.47M
and capital expenditures -57.05M, giving a free cash flow of -239.52M.
Operating Cash Flow -182.47M Capital Expenditures -57.05M Free Cash Flow -239.52M FCF Per Share -2.57
Full Cash Flow Statement Margins Gross margin is 77.68%, with operating and profit margins of -20.28% and -21.17%.
Gross Margin 77.68% Operating Margin -20.28% Pretax Margin -21% Profit Margin -21.17% EBITDA Margin -11.18% EBIT Margin -20.28% FCF Margin -34.85%
